Model List of Essential Medicines

Alprostadil (prostaglandin E1)

Section	Indications
Medicines administered to the neonate [c] ◦ Parenteral > General injections > IV: 0.5 mg per mL in alcohol	Other specified congenital anomaly of great arteries including arterial duct

Anastrozole

Section	Indications
Ovulation inducers ◦ Oral > Solid: 1 mg tablet	Therapeutic equivalent to letrozole for Female infertility without specification whether primary or secondary

Beractant

Section	Indications
Medicines administered to the neonate [c] ◦ Respiratory > Suspension: 25 mg per mL for intratracheal instillation	Respiratory distress syndrome of newborn

Caffeine citrate

Section	Indications
Medicines administered to the neonate [c] ◦ Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL) ◦ Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)	Apnoea of newborn

Carbetocin

Section	Indications
Uterotonics ◦ Parenteral > General injections > IV: 100 µg per mL (heat stable)	Postpartum haemorrhage

Chlorhexidine

Section	Indications
Medicines administered to the neonate [c] ◦ Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine) ◦ Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)	Omphalitis of newborn

Clomifene

Section	Indications
Ovulation inducers ◦ Oral > Solid: 50 mg (citrate)	Female infertility without specification whether primary or secondary

Condoms

Section	Indications
Barrier methods ◦ -	Contact with health services for contraceptive management

Copper-containing intrauterine device

Section	Indications
Intrauterine devices ◦ -	Contact with health services for insertion of contraceptive device

Dexamethasone

Section	Indications
Other medicines administered to the mother ◦ Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))	Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

Diaphragms

Section	Indications
Barrier methods ◦ -	Contact with health services for contraceptive management

Dinoprostone (prostaglandin E2)

Section	Indications
Medicines administered to the neonate [c] ◦ Parenteral > General injections > IV: 1 mg per mL	Therapeutic equivalent to alprostadil (prostaglandin E1) for Other specified congenital anomaly of great arteries including arterial duct Other specified congenital anomaly of great arteries including arterial duct

Ergometrine

Section	Indications
Uterotonics ◦ Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)	Postpartum haemorrhage

Estradiol cypionate + medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives ◦ Parenteral > General injections > IM: 5 mg + 25 mg	Contact with health services for reasons associated with reproduction

Ethinylestradiol + etonogestrel

Section	Indications
Intravaginal contraceptives ◦ Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg	Contact with health services for contraceptive management

Ethinylestradiol + levonorgestrel

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 50 µg + 250 µg [4] ◦ Oral > Solid: 30 µg + 150 µg	Contact with health services for postcoital contraception Contact with health services for contraceptive management

Ethinylestradiol + norethisterone

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 35 µg + 1 mg	Contact with health services for contraceptive management

Etonogestrel-releasing implant

Section	Indications
Implantable contraceptives ◦ Implant > Subdermal: 68 mg single rod	Contact with health services for insertion of contraceptive device

Ibuprofen

Section	Indications
Medicines administered to the neonate [c] ◦ Parenteral > General injections > IV: 5 mg per mL	Patent arterial duct

Indometacin

Section	Indications
Medicines administered to the neonate [c]	Therapeutic equivalent to ibuprofen for Patent arterial duct

Letrozole

Section	Indications
Ovulation inducers ◦ Oral > Solid > dosage form: 2.5 mg	Female infertility without specification whether primary or secondary

Levonorgestrel

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 750 µg [2]; 1.5 mg [1] ◦ Oral > Solid: 30 µg	Contact with health services for postcoital contraception Contact with health services for contraceptive management
Intrauterine devices ◦ Intrauterine system with reservoir containing 52 mg of levonorgestrel.	Contact with health services for insertion of contraceptive device

Levonorgestrel-releasing implant

Section	Indications
Implantable contraceptives ◦ Implant > Subdermal: 75 mg per rod (two-rods)	Contact with health services for insertion of contraceptive device

Medroxyprogesterone acetate

Section	Indications
Injectable hormonal contraceptives ◦ Parenteral > General injections > IM: 150 mg per mL in 1 mL vial ◦ Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system	Contact with health services for reasons associated with reproduction

Methylergometrine

Section	Indications
Uterotonics	Therapeutic equivalent to ergometrine for Postpartum haemorrhage

Mifepristone - misoprostol

Section	Indications
Medicines for medical abortion ◦ Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package	Unspecified time of fetal death, cause not specified Induced abortion

Misoprostol

Section	Indications
Uterotonics ◦ Local > Vaginal > tablet: 25 µg ◦ Oral > Solid: 200 µg	Unspecified obstetric condition Postpartum haemorrhage
Medicines for medical abortion ◦ Oral > Solid > tablet: 200 µg	Spontaneous abortion, incomplete, without complication

Multiple micronutrient supplement

Section	Indications
Other medicines administered to the mother ◦ Tablet containing: ◦ Vit A: 800 mcg retinol activity equivalent ◦ Vit C: 70 mg ◦ Vit D: 5 mcg (200 IU) ◦ Vit E: 10 mg alpha tocopherol equivalent ◦ Vit B1: 1.4 mg ◦ Vit B2: 1.4 mg ◦ Vit B3: 18 mg niacin equivalent ◦ Vit B6: 1.9 mg ◦ Folic acid: 400 mcg ◦ Vit B12: 2.6 mcg ◦ Iron: 30 mg ◦ Iodine: 150 mcg ◦ Zinc: 15 mg ◦ Selenium: 65 mcg ◦ Copper: 2 mg	Maternal care for other specified conditions predominantly related to pregnancy

Nifedipine

Section	Indications
Antioxytocics (tocolytics) ◦ Oral > Solid: 10 mg (immediate-release)	Preterm labour without delivery

Norethisterone

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 350 µg	Contact with health services for contraceptive management

Norethisterone enantate

Section	Indications
Injectable hormonal contraceptives ◦ Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution	Contact with health services for reasons associated with reproduction

Oxytocin

Section	Indications
Uterotonics ◦ Parenteral > General injections > unspecified: 10 IU per mL	Postpartum haemorrhage

Porcatant alfa

Section	Indications
Medicines administered to the neonate [c] ◦ Respiratory > Suspension: 80 mg per mL for intratracheal instillation	Respiratory distress syndrome of newborn

Progesterone vaginal ring

Section	Indications
Intravaginal contraceptives ◦ Local > Vaginal > vaginal ring: 2.074 g micronized progesterone	Contact with health services for contraceptive management

Tranexamic acid

Section	Indications
Other medicines administered to the mother ◦ Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Postpartum haemorrhage

Ulipristal

Section	Indications
Oral hormonal contraceptives ◦ Oral > Solid: 30 mg tablet (ulipristal acetate)	Contact with health services for postcoital contraception